Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Lindström

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Medicinal Chemistry|February 28, 2018
Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure-Based Drug DesignFredrik Rahm, Jenny Viklund, Lionel Trésaugues, et al.
ACS Chemical Biology|July 6, 2017
Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer TargetManuel Ellermann, Ashley Eheim, Fredrik Rahm, et al.
Molecular Oncology|March 20, 2024
Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacyYasmin Yu, Madhumita Bogdan, Muhammad Zaeem Noman, et al.
Journal of Medicinal Chemistry|August 29, 2012
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptidesBritt-Marie Swahn, Karin Kolmodin, Sofia Karlström, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Medicinal Chemistry|February 28, 2018
Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure-Based Drug DesignFredrik Rahm, Jenny Viklund, Lionel Trésaugues, et al.
ACS Chemical Biology|July 6, 2017
Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer TargetManuel Ellermann, Ashley Eheim, Fredrik Rahm, et al.
Molecular Oncology|March 20, 2024
Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacyYasmin Yu, Madhumita Bogdan, Muhammad Zaeem Noman, et al.
Journal of Medicinal Chemistry|August 29, 2012
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptidesBritt-Marie Swahn, Karin Kolmodin, Sofia Karlström, et al.
Pageof 3